605 related articles for article (PubMed ID: 19793694)
1. [Detection of ototoxic effect of cisplatin with otoacoustic emission in testicular cancer patients].
Biró K
Magy Onkol; 2009 Sep; 53(3):279-83. PubMed ID: 19793694
[TBL] [Abstract][Full Text] [Related]
2. Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission.
Biro K; Noszek L; Prekopp P; Nagyiványi K; Géczi L; Gaudi I; Bodrogi I
Oncology; 2006; 70(3):177-84. PubMed ID: 16757924
[TBL] [Abstract][Full Text] [Related]
3. [Detection of late ototoxic side effect of cisplatin by distortion otoacoustic emission (DPOAE)].
Biró K; Noszek L; Prekopp P; Nagyiványi K; Géczi L; Gaudi I; Bodrogi I
Magy Onkol; 2006; 50(4):329-35. PubMed ID: 17216007
[TBL] [Abstract][Full Text] [Related]
4. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D
Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
[TBL] [Abstract][Full Text] [Related]
5. Ototoxicity risk assessment combining distortion product otoacoustic emissions with a cisplatin dose model.
Dille MF; McMillan GP; Reavis KM; Jacobs P; Fausti SA; Konrad-Martin D
J Acoust Soc Am; 2010 Sep; 128(3):1163-74. PubMed ID: 20815453
[TBL] [Abstract][Full Text] [Related]
6. [Tinnitus in noise-induced hearing impairment].
Kowalska S; Sułkowski W
Med Pr; 2001; 52(5):305-13. PubMed ID: 11828843
[TBL] [Abstract][Full Text] [Related]
7. [Hearing loss caused by high dose carboplatin therapy].
Lautermann J; Adamczyk M; ten Cate WJ; Kloke O
Laryngorhinootologie; 1998 Feb; 77(2):82-4. PubMed ID: 9555700
[TBL] [Abstract][Full Text] [Related]
8. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions.
Knight KR; Kraemer DF; Winter C; Neuwelt EA
J Clin Oncol; 2007 Apr; 25(10):1190-5. PubMed ID: 17401008
[TBL] [Abstract][Full Text] [Related]
9. Early ototoxic changes in patients with germ cell tumor after first cycle of cisplatin-based therapy.
Noszek L; Budai B; Prekopp P; Széchenyi R; Szőnyi M; Talpai S; Nagyiványi K; Bíró K; Géczi L
Laryngoscope; 2017 Aug; 127(8):E277-E282. PubMed ID: 27666741
[TBL] [Abstract][Full Text] [Related]
10. Effect of high-dose cisplatin on auditory brainstem responses and otoacoustic emissions in laboratory animals.
Sockalingam R; Freeman S; Cherny TL; Sohmer H
Am J Otol; 2000 Jul; 21(4):521-7. PubMed ID: 10912698
[TBL] [Abstract][Full Text] [Related]
11. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss.
Bertolini P; Lassalle M; Mercier G; Raquin MA; Izzi G; Corradini N; Hartmann O
J Pediatr Hematol Oncol; 2004 Oct; 26(10):649-55. PubMed ID: 15454836
[TBL] [Abstract][Full Text] [Related]
12. [Effect of inner ear hearing loss on delayed otoacoustic emissions (TEOAE) and distortion products (DPOAE)].
Hoth S
Laryngorhinootologie; 1996 Dec; 75(12):709-18. PubMed ID: 9081275
[TBL] [Abstract][Full Text] [Related]
13. Distortion product otoacoustic emissions: an objective technique for the screening of hearing loss in children treated with platin derivatives.
Dhooge I; Dhooge C; Geukens S; De Clerck B; De Vel E; Vinck BM
Int J Audiol; 2006 Jun; 45(6):337-43. PubMed ID: 16777780
[TBL] [Abstract][Full Text] [Related]
14. Left-right asymmetry in hearing loss following cisplatin therapy in children--the left ear is slightly but significantly more affected.
Schmidt CM; Knief A; Lagosch AK; Deuster D; am Zehnhoff-Dinnesen A
Ear Hear; 2008 Dec; 29(6):830-7. PubMed ID: 18772725
[TBL] [Abstract][Full Text] [Related]
15. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Schornagel JH; Dreschler WA; Rasch CR; Balm AJ
J Clin Oncol; 2007 Aug; 25(24):3759-65. PubMed ID: 17704425
[TBL] [Abstract][Full Text] [Related]
16. [Otoacoustic emissions measurements in children during the chemotherapy because of the acute lymphoblastic leukemia].
Lisowska G; Namysłowski G; Hajduk A; Polok A; Tomaszewska R; Misiołek M
Otolaryngol Pol; 2006; 60(3):415-20. PubMed ID: 16989457
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors.
Oldenburg J; Kraggerud SM; Cvancarova M; Lothe RA; Fossa SD
J Clin Oncol; 2007 Feb; 25(6):708-14. PubMed ID: 17228018
[TBL] [Abstract][Full Text] [Related]
18. Evoked otoacoustic emissions--an approach for monitoring cisplatin induced ototoxicity in children.
Stavroulaki P; Apostolopoulos N; Segas J; Tsakanikos M; Adamopoulos G
Int J Pediatr Otorhinolaryngol; 2001 May; 59(1):47-57. PubMed ID: 11376818
[TBL] [Abstract][Full Text] [Related]
19. [Effects of Cisplatin on Auditory Function in Children with cancer. Otoacoustic Emission Evaluation].
Toral-Martiñón R; Poblano A; Collado-Corona MA; González R
Gac Med Mex; 2003; 139(6):529-34. PubMed ID: 14723047
[TBL] [Abstract][Full Text] [Related]
20. Newborn hearing screening by transient evoked otoacoustic emissions: analysis of response as a function of risk factors.
De Capua B; De Felice C; Costantini D; Bagnoli F; Passali D
Acta Otorhinolaryngol Ital; 2003 Feb; 23(1):16-20. PubMed ID: 12812130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
